Brief: Lixte Biotechnology Receives Counter-Signed Termination Letter for License Agreement With Moffitt
Oct 5 (Reuters) - Lixte Biotechnology Holdings Inc
LIXT.O :
* LIXTE BIOTECHNOLOGY HOLDINGS INC - ON OCT 4, RECEIVED A
COUNTER-SIGNED TERMINATION LETTER DATED SEPTEMBER 29, 2023
* LIXTE BIOTECHNOLOGY- TERMINATION LETTER WITH RESPECT TO
EXCLUSIVE LICENSE AGREEMENT DATED AUG 20, 2018 BETWEEN CO AND
MOFFITT EFFECTIVE SEPT 30, 2023
Further company coverage: LIXT.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on NOMAD Power Solutions
See all newsBrief: Nomad Power Solutions Files 2026 Second Quarter Form 10-Q, Provides Business Update
U.S. STOCKS ON THE MOVE-SpaceX, Tesla, Woodside Energy Group
U.S. STOCKS ON THE MOVE-SpaceX, SharonAI, Medline
U.S. STOCKS ON THE MOVE-SpaceX, SharonAI, Medline
LIXTE to buy battery firm NOMAD, shifts away from cancer drugs; shares rise